M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more

seekingalpha
2024-11-03

Edwin Tan

Companies that grabbed headlines in the deals space include:

AbbVie (NYSE:ABBV) has agreed to acquire all outstanding equity of neuroscience-focused biotech Aliada Therapeutics for $1.4B in cash.

Stericycle (NASDAQ:SRCL) disclosed that all the closing conditions for its planned $ 62-a-share sale to Waste Management (NYSE:WM) have been received.

Maersk (OTCPK:AMKBY) CEO Vincent Clerc said the shipping and logistics company won't be participating in the GXO Logistics (NYSE:GXO) sales process.

Blackstone (NYSE:BX) is the mystery investor who bid for a $7 billion minority stake in Roger Communication Inc.'s (NYSE:RCI) cell phone infrastructure business.

Siemens (OTCPK:SIEGY) (OTCPK:SMAWF) agreed to buy Altair Engineering (NASDAQ:ALTR) for $113 a share in cash, or a total deal value of $10.6 billion, the companies announced Wednesday.

Take-Two Interactive (NASDAQ:TTWO) ticks higher on report it's in talks to sell adtech division.

Cleveland-Cliffs (NYSE:CLF) said it won the final approvals needed for its planned $2.5 billion purchase of Stelco (OTCPK:STZHF) and the deal is scheduled to close on Friday.

GSK (NYSE:GSK) has agreed to acquire lupus drug candidate CMG1A46 from Chimagen Biosciences for $300M upfront plus potential milestone payments of up to $550M.

GlycoMimetics (NASDAQ:GLYC) soared 155% in premarket trade after it said it has entered into an acquisition agreement with privately-held firm, Crescent Biopharma.

Rapid7 (NASDAQ:RPD) surged 4.5% after a report that it's exploring options after getting takeover interest from private equity shops.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10